Clinical Trial Update: Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

This Phase 2 trial investigates minimal residual disease-guided maintenance therapy with belantamab mafodotin and lenalidomide after autologous hematopoietic ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• Revlimid (lenalidomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloma Multiple | Phase 2 | Status: RECRUITING